Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

October 21, 2022

Evan J. Lipson, MD, discusses the effect of preoperative nivolumab plus relatlimab in resectable non-small cell lung cancer (NSCLC).

October 17, 2022

Drs Ramkumar and Morganstein discuss the challenges they face with integrating and organizing molecular testing results into electronic medical records, how they address non–small cell lung cancer test results with patients, and their hopes for the future of pathology at their institutions.

October 05, 2022

Cesar A. Santa-Maria, MD, discusses exploratory data seen with trastuzumab deruxtecan in patients with triple-negative breast cancer.

September 02, 2022

A dramatic presentation at the 2022 American Society of Clinical Oncology Annual Meeting changed treatment standards seemingly overnight for women with previously treated metastatic HER2-low breast cancer. However, fundamental questions remain.

August 25, 2022

Dr Levy discusses the significance of the FDA approval of trastuzumab deruxtecan in HER2-mutant NSCLC, the pivotal efficacy and safety data from the DESTINY-Lung02 trial, and the optimal use of companion diagnostic tests in the field.

August 19, 2022

Benjamin Levy, MD, discusses the significance of the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.

August 19, 2022

Benjamin Levy, MD, discusses treatment considerations for the integration of trastuzumab deruxtecan into practice and what this approval signals for the future of the field.

August 09, 2022

The combination of datopotamab deruxtecan and pembrolizumab, with or without platinum-based chemotherapy, displayed promising efficacy and a manageable safety profile in patients with advanced/metastatic non–small cell lung cancer.

July 25, 2022

Twelve years after key research into immune checkpoint inhibitor therapy first made a splash at the American Society of Clinical Oncology Annual Meeting, evidence continues to mount that supports the durability of these agents in a range of cancers.

July 24, 2022

Judith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..

July 24, 2022

Judith Karp, MD, Azra Raza, MD,, and Michelle M. Le Beau, PhD, discuss how their gender has shaped their professional lives, from working as some of the only female clinical faculty at their institutions to being compared to their male colleagues and denied opportunities when working independently from men.

July 22, 2022

Jacob J. Adashek, DO, discusses how targeting molecular alterations is key for treating multiple types of cancer.

July 16, 2022

Julie R. Brahmer, MD, MSc, discusses the examination of nemvaleukin alfa in solid tumors.

July 11, 2022

Mark C. Markowski, MD, PhD, discusses the evaluation of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer.

July 11, 2022

Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, share the challenges they chose to mold into career goals, including developing a new technology to study cell cytokinetics, identifying gene phenotypes, and recognizing that leukemia diseases stem from the same root issues in DNA.

July 08, 2022

Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, highlight the decades-long evolution of the leukemia field and express challenges such as defining the causes of leukemia and developing therapies to treat the disease and mitigate adverse effects like bone pain.

June 30, 2022

Evan J. Lipson, MD, discusses the current treatment landscape in locally advanced, unresectable, or metastatic basal cell carcinoma.

June 27, 2022

Drs Karp, Raza, and Le Beau discuss challenges they faced in their early careers as women in leukemia, the ways they overcame those obstacles, and the unique pitfalls and successes they’ve experienced as female physicians.

February 07, 2022

Concurrent chemoradiation followed by durvalumab has become the standard of care for patients with unresectable stage III non–small cell lung cancer based on the results of the phase 3 PACIFIC trial. However, several strategies are under clinical evaluation to push the paradigm beyond the PACIFIC regimen.

January 14, 2022

Christian Frederick Meyer, MD, PhD, MS, discusses standard treatment options in cardiac angiosarcoma.